[HTML][HTML] Anti-IL6 treatment of serious COVID-19 disease: A monocentric retrospective experience
L Castelnovo, A Tamburello, A Lurati, E Zaccara… - Medicine, 2021 - journals.lww.com
COVID-19 is causing a high influx of patients suffering from serious respiratory
complications leading the necessity to find effective therapies. These patients seem to …
complications leading the necessity to find effective therapies. These patients seem to …
Clinical outcomes in COVID‐19 patients treated with tocilizumab: an individual patient data systematic review
D Antwi‐Amoabeng, Z Kanji, B Ford… - Journal of medical …, 2020 - Wiley Online Library
Background Current evidence suggests an important role of the interleukin‐6 (IL‐6) pathway
in severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)‐related cytokine …
in severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)‐related cytokine …
[HTML][HTML] Potential role of anti-interleukin (IL)-6 drugs in the treatment of COVID-19: rationale, clinical evidence and risks
S Crisafulli, V Isgro, L La Corte, F Atzeni, G Trifiro - BioDrugs, 2020 - Springer
The epidemic due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
infection has been spreading globally, raising increasing concerns. This public health …
infection has been spreading globally, raising increasing concerns. This public health …
Higher levels of IL‐6 early after tocilizumab distinguish survivors from nonsurvivors in COVID‐19 pneumonia: A possible indication for deeper targeting of IL‐6
L Quartuccio, A Sonaglia, D Pecori… - Journal of medical …, 2020 - Wiley Online Library
Introduction The most serious COVID‐19 deriving from severe acute respiratory syndrome
coronavirus 2 causes a cytokine release storm and it is associated with worse outcomes. In …
coronavirus 2 causes a cytokine release storm and it is associated with worse outcomes. In …
[HTML][HTML] Tocilizumab improves the prognosis of COVID-19 in patients with high IL-6
R Flisiak, J Jaroszewicz, M Rogalska… - Journal of Clinical …, 2021 - mdpi.com
Despite direct viral effect, the pathogenesis of coronavirus disease 2019 (COVID-19)
includes an overproduction of cytokines including interleukin 6 (IL-6). Therefore, tocilizumab …
includes an overproduction of cytokines including interleukin 6 (IL-6). Therefore, tocilizumab …
Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis
R Rossotti, G Travi, N Ughi, M Corradin, C Baiguera… - Journal of Infection, 2020 - Elsevier
Background As the novel SARS-CoV-2 pandemic occurred, no specific treatment was yet
available. Inflammatory response secondary to viral infection might be the driver of severe …
available. Inflammatory response secondary to viral infection might be the driver of severe …
[HTML][HTML] IL-6 inhibitors in the treatment of serious COVID-19: a promising therapy?
S Atal, Z Fatima - Pharmaceutical medicine, 2020 - Springer
At present, there are no proven agents for treatment of coronavirus disease (COVID-19). The
available evidence has not allowed guidelines to clearly recommend any drugs outside the …
available evidence has not allowed guidelines to clearly recommend any drugs outside the …
[PDF][PDF] A systematic review on the efficacy and safety of IL-6 modulatory drugs in the treatment of COVID-19 patients.
J Solis-Garcia Del Pozo, MF Galindo… - European Review for …, 2020 - europeanreview.org
The pandemic caused by the new SARS-CoV2 coronavirus has led to an effort to find
treatments that are effective against this disease that the World Health Organization calls …
treatments that are effective against this disease that the World Health Organization calls …
[HTML][HTML] Interleukin-6 (IL-6) inhibitors as therapeutic agents for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis
RT Pinzon, VO Wijaya, RB Buana - Journal of infection and public health, 2021 - Elsevier
Introduction Preliminary studies showed that coronavirus disease 2019 (COVID-19) disrupts
body immune system, including dysregulation of cytokine interleukin-6 (IL-6). IL-6 inhibitors …
body immune system, including dysregulation of cytokine interleukin-6 (IL-6). IL-6 inhibitors …
Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?
Y Zhang, Y Zhong, L Pan, J Dong - Drug discoveries & therapeutics, 2020 - jstage.jst.go.jp
The world is in the midst of the coronavirus disease 2019 (COVID-19) pandemic. Interleukin
6 (IL-6) inhibitor (tocilizumab) had been suggested for the treatment of acute respiratory …
6 (IL-6) inhibitor (tocilizumab) had been suggested for the treatment of acute respiratory …